Immunohistochemical expression of HR23B has been reported to correlate with responses to HDAC inhibitors in cutaneous T-cell lymphoma, with high HR23B expression having a positive predictive value of 71.7% for clinical benefit (partial response or stable disease) [18]. The gene discussed is RAD23B; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.